Patient Square Capital LP Cullinan Oncology, Inc. Transaction History
Patient Square Capital LP
- $267 Billion
- Q4 2024
A detailed history of Patient Square Capital LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Patient Square Capital LP holds 878,897 shares of CGEM stock, worth $7.94 Million. This represents 4.0% of its overall portfolio holdings.
Number of Shares
878,897
Previous 824,705
6.57%
Holding current value
$7.94 Million
Previous $13.8 Billion
22.46%
% of portfolio
4.0%
Previous 5.12%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
67.1MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$69.1 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$51.9 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$32.1 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$30.8 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$30.5 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $412M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...